论文部分内容阅读
目的:探讨乌司他丁联合奥曲肽治疗重症急性胰腺炎的临床效果。方法:选取2015年7月-2016年8月于本院收治的重症胰腺炎患者93例,随机分为乌司他丁组,奥曲肽组和联合治疗组。除基础治疗外,乌司他丁组加用乌司他丁,奥曲肽组加用奥曲肽,联合治疗组加用以上两药,观察3组疗效。结果:治疗2周后,联合治疗组的总有效率(90.3%)明显高于乌司他丁组(80.6%)与奥曲肽组(83.9%),差异有统计学意义(P<0.05)。结论:乌司他丁联合奥曲肽治疗重症急性胰腺炎的临床效果较单药治疗好,且安全性高,值得临床推广。
Objective: To investigate the clinical effect of ulinastatin and octreotide in the treatment of severe acute pancreatitis. Methods: Ninety-three patients with severe pancreatitis admitted to our hospital from July 2015 to August 2016 were randomly divided into ulinastatin group, octreotide group and combination therapy group. In addition to the basic treatment, ulinastatin group plus ulinastatin, octreotide group plus octreotide, combined treatment group plus the above two drugs to observe the efficacy of three groups. Results: After 2 weeks of treatment, the total effective rate (90.3%) in combination therapy group was significantly higher than that in ulinastatin group (80.6%) and octreotide group (83.9%) (P <0.05). Conclusion: The clinical effect of ulinastatin combined with octreotide in treatment of severe acute pancreatitis is better than that of monotherapy, and it is safe and worthy of clinical promotion.